Mayo Clinic Unveils an Early Alzheimer’s Risk Tool That Works Well but Isn’t Ready for Real-World Use

The Alzheimer’s Risk Calculator That Won’t Save the World—Yet

A Mayo Clinic breakthrough offers precision when the field needs scale

ROCHESTER, Minn. — When Mayo Clinic researchers announced they could predict a person’s Alzheimer’s risk years before the first memory slip, the news release sounded triumphant. It promised a groundbreaking tool, more personalized care, and precious time for patients and families. Yet a few awkward truths never made it into the headlines. The tool leans on a $5,000 brain scan most people can’t get, it’s been validated mostly in white Midwesterners, and it arrives just as the rest of the field is sprinting toward inexpensive blood tests that may make the whole approach feel dated.

That tension says a lot about where Alzheimer’s science stands in 2025. The research is sophisticated and technically dazzling. The real world, however, needs something simpler, cheaper, and much easier to scale.

What Mayo Actually Built

The new tool, published in The Lancet Neurology, deserves real scientific credit. Drawing on 5,858 volunteers from the long-running Mayo Clinic Study of Aging, a team including radiologist Clifford Jack Jr. and neurologist Ronald Petersen developed a calculator that estimates a person’s 10-year and lifetime risk of cognitive decline. It blends age, sex, APOE gene variants, and—most importantly—amyloid plaque levels measured through PET imaging.

Their methods go far beyond the typical academic model. Most studies lose track of participants who drop out along the way. Mayo didn’t. Thanks to Olmsted County’s unusually integrated medical record system, statistician Terry Therneau and the team kept following people long after they vanished from the study schedule. That let them spot a striking bias: dementia rates in dropouts were twice as high as in those who stayed. Because of that, most earlier models ended up underestimating risk.

Scientists who reviewed the work called it top-tier, and it’s hard to disagree. It delivers the clearest amyloid-based risk curves yet from everyday people rather than a hand-picked clinical trial group. In many ways, it does for Alzheimer’s what the famous Framingham model did for heart disease decades ago—turns biological markers into meaningful probabilities.

The PET Problem

This is where the story twists. The entire model depends on amyloid PET scans. Those scans provide a crisp picture of brain pathology, but they’re pricey, limited in availability, and now being overtaken by far simpler blood tests.

Back in May 2025, the FDA cleared Fujirebio’s Lumipulse blood test for detecting Alzheimer’s-related changes. It matches PET scans 92 percent of the time and costs far less. Roche’s rival test works on thousands of lab machines already installed around the world. Quanterix is pushing toward even greater sensitivity. You can feel the shift: blood tests have become the front door for Alzheimer’s detection, with PET scans moving into a supporting role for complicated cases.

That puts Mayo in an awkward spot. Their tool is built entirely around PET numbers. It hasn’t been translated for use with blood biomarkers, which means it risks becoming a brilliant but niche instrument—like building the world’s finest steam engine right as the electric grid lights up.

Another issue shadows it. Olmsted County is overwhelmingly white and relatively affluent. Its residents don’t fully reflect the communities where dementia risk is soaring. So while the press release promised “more personalized care,” the reality is that the model simply hasn’t been tested across the broad range of people who most need early detection.

The Investment Calculus

Investors watching all this don’t need rose-colored glasses. They can see the value and the limitations. Mayo has created a high-end piece of intellectual property, but it hasn’t yet grown into a commercial product.

The overall market is gigantic. Dementia already costs more than $1.3 trillion each year. By 2050, about 139 million people will live with the condition. Alzheimer’s diagnostics alone could represent a $15–22 billion market by 2030. But having a big market doesn’t guarantee that a tool will find its footing.

If you score Mayo’s model on the basics, it might earn something like 7.5/10 for scientific value, 4/10 for immediate commercial viability, and 6/10 for long-term potential—if it becomes part of a broader technology platform. That “if” carries weight.

In the short term, the most likely revenue stream comes from partnerships with pharmaceutical companies. The model could help recruit the right trial participants or refine study endpoints. That’s steady business but not world-changing. To make a real commercial leap, Mayo needs one of three things.

First, it must adapt the calculator to blood-based biomarkers. If the risk engine could run on data from widely used tests by Roche or Fujirebio, it would instantly become scalable. Without that, those companies may simply build their own engines and lock in their customer base.

Second, Mayo would need regulatory clearance as a Software as a Medical Device. That requires proving the score actually changes clinical decisions and improves patient outcomes. Securing that evidence will take time—likely three to five years—and serious investment. Mayo has prestige, but turning prestige into a billable medical tool demands operational muscle that academic institutions don’t always have.

Third, the team could strike a strategic partnership with a diagnostics giant or a digital health company. Imagine combining Mayo’s risk engine with Altoida’s augmented-reality cognitive biomarkers or Linus Health’s iPad-based assessments. That would create a layered system: quick digital screening, a risk score, then confirmatory imaging. It would look a lot more like a product people could actually use.

Investors should watch for certain signals: a blood biomarker version, long-term outcome studies, regulatory submissions, and licensing deals. A Mayo-connected spinout that fuses blood tests, digital markers, and genetics into a clear software pathway would definitely be worth attention.

What This Means

Mayo’s tool doesn’t solve the bottleneck in Alzheimer’s care. What it does is shine a spotlight on it. The field desperately needs reliable risk stratification, especially now that drugs like lecanemab can slow decline a bit. Yet precision without accessibility doesn’t help the millions who need it most.

The true breakthrough will come when someone blends inexpensive blood tests for early screening, digital tools for ongoing monitoring, and rigorous risk algorithms like Mayo’s into a system that works in an ordinary doctor’s office. That’s the prize. Not this model alone, but the larger platform that can absorb it and deploy it at scale.

For now, Mayo has produced what some analysts call “prime platform science”—the kind of foundational knowledge that strengthens its role as a data powerhouse in early detection. Whether it becomes something more depends on decisions the press release didn’t discuss: who gets access to the model, how fast it evolves beyond PET, and whether Mayo can match its scientific precision with real-world execution.

Those choices will reveal whether this becomes another impressive academic paper or the cornerstone of a future in which we finally get ahead of Alzheimer’s disease.

NOT INVESTMENT ADVICE